Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $868.50 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:09 PM 08/13/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $895.65
52 Week Low
11/4/14 - $615.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi-adr (SNYN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi-adr (SNYN) Key Developments

Evotec, Apeiron Biologics and Sanofi Jointly Develop Novel Small Molecule-Based Cancer Immunotherapies

Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic cancers by enhancing the anti-tumour activity of human lymphocytes. Based on Evotec’s technological expertise and Apeiron Biologics’ immunological know-how, the collaboration will also focus on the identification of novel small molecule hits and their targets for next-generation therapies in immuno-oncology which are expected to complement the current offerings of checkpoint inhibitors. The collaboration is set up as an initiative to support long-term pipeline building for Evotec, Apeiron Biologics and Sanofi. All three companies will make significant contributions to this collaboration in terms of scientific expertise, technological platforms and resources. The collaboration will further enhance and complement Sanofi’s extensive oncology portfolio. It will enable Evotec to enter into the drug discovery area of immuno-oncology and it will substantially support Apeiron Biologics’ strategy focusing on novel and innovative checkpoint inhibiting approaches. The agreement triggers two years of substantial research payments for Evotec and Apeiron Biologics with the opportunity to receive pre-clinical, clinical, regulatory and commercial milestones which could total over €200 million as well as royalties upon commercialisation.

Sanofi and Evotec Align Forces to Develop Next Generation Therapies in Diabetes

Evotec AG and Sanofi announced a strategic collaboration in the field of diabetes. The goal of this collaboration will be to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells. In addition, Sanofi and Evotec will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics. Both companies will make significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration will further enhance and complement Sanofi’s extensive diabetes portfolio and will extend Evotec’s metabolic disease and stem cell-based drug discovery programs. The agreement between Evotec and Sanofi triggers an upfront payment of €3 million, potential pre-clinical, clinical, regulatory and commercial milestones which could total over €300 million as well as significant royalties and research payments.

Sanofi's Insulin Toujeo® Available for the Treatment of Adults with Diabetes in the UK

Sanofi announced that Toujeo® (insulin glargine [rDNA origin] 300 units/mL), a long-acting, once-daily basal insulin treatment is available for clinicians to prescribe in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition. Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus® (insulin glargine 100 units/mL) currently used in the treatment of diabetes. There are currently 3.3 million people in the UK diagnosed with diabetes a figure predicted to rise to an estimated five million people by 2025. Over two thirds of adults treated with insulin do not reach the National Institute for Health and Care Excellence (NICE) target for blood glucose control (HbA1c = 7.5%), increasing their risk of potentially avoidable complications such as amputation, blindness and renal disease. Many clinicians cite concern of hypoglycaemia as a reason for not managing blood glucose more aggressively - three quarters (75.5%) of specialists would be more aggressive in treating diabetes if there was no concern about hypoglycaemia. For patients, concern over hypoglycaemia may cause them to modify their insulin dose - four out of ten people with type 2 diabetes reduce their insulin dose after an episode of mild hypoglycaemia and six out of ten after a severe hypoglycaemic episode. Results from clinical trials evaluating the efficacy and tolerability of insulin glargine 300 units/mL compared to insulin glargine 100 units/mL demonstrated a similar blood glucose (HbA1c) reduction with a lower incidence of confirmed hypoglycaemia in patients with type 2 diabetes on insulin glargine 300 units/mL compared to those on insulin glargine 100 units/ml. In patients with type 1 diabetes, trials demonstrated similar blood glucose (HbA1c) reduction but showed no difference in confirmed hypoglycaemia. Insulin glargine 300 units/mL also showed a more stable and more prolonged glucose lowering effect that lasted beyond 24 hours, and low within-individual blood-sugar variability. Insulin glargine 300 units/mL was licensed by the European Medicines Agency (EMA) in February 2015. It has also been licensed by the U.S. Food and Drug Administration (FDA) and is under review by other regulatory authorities around the world. Insulin glargine 300 units/mL forms a compact subcutaneous depot with a reduced surface area and allows for a slower, more prolonged release of insulin glargine beyond 24 hours. Insulin glargine 300 units/mL and insulin glargine 100 units/mL are not bioequivalent and therefore are not interchangeable. Switching from once-daily insulin glargine 300 units/mL, to insulin glargine 100 units/mL results in an increased risk of hypoglycaemic events, mainly in the first week after the switch. To reduce this risk, patients should reduce their dose by 20%. When switching to or from insulin glargine 300 units/mL, close metabolic monitoring is recommended during the transition and in the initial weeks thereafter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $868.50 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $64.51 USD +1.37
Amgen Inc $155.72 USD +1.74
Bayer AG €121.20 EUR +1.89
Medtronic PLC $73.52 USD +1.28
Novo Nordisk A/S kr370.10 DKK +13.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SNYN Industry Range
Price/Earnings 23.6x
Price/Sales 3.1x
Price/Book 2.0x
Price/Cash Flow 15.6x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at